CN103505535A - Medicine used for treating psoriasis as well as extraction method, extract and application thereof - Google Patents
Medicine used for treating psoriasis as well as extraction method, extract and application thereof Download PDFInfo
- Publication number
- CN103505535A CN103505535A CN201210225558.0A CN201210225558A CN103505535A CN 103505535 A CN103505535 A CN 103505535A CN 201210225558 A CN201210225558 A CN 201210225558A CN 103505535 A CN103505535 A CN 103505535A
- Authority
- CN
- China
- Prior art keywords
- medicine
- parts
- extract
- crude drug
- radix
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention provides a medicine used for treating psoriasis as well as an extraction method, extract and an application thereof. The medicine used for treating psoriasis is prepared from the following raw materials in parts by weight: 6-10 parts of bulgaria inquinans, 6-12 parts of Chinese angelica, 6-15 parts of cortex dictamni and 3-9 parts of liquorice. The medicine used for treating psoriasis has the effects of relieving itching, calming, activating blood, dissipating stasis, reducing blood viscosity, improving microcirculation, clearing heat, drying dampness, detoxifying and resisting to bacteria, has a certain photodynamic effect and can enhance the treatment effect, so that the medicine used for treating psoriasis has an especially obvious psoriasis treatment effect.
Description
Technical field
The invention belongs to Chinese medicine composition field, in particular to a kind of psoriatic medicine and preparation method thereof for the treatment of.
Background technology
Psoriasis (Psoriasis), claims again psoriasis, is a kind of common chronic dermatosis, it is characterized in that occurring the pimple, the erythema that differ in size, and surface coverage silvery white squama, and clear border is apt to occur in scalp, extremity Shen Ceji back.Male is more than women.Easily recur or increase the weight of winter in spring, and alleviate summer and autumn more.
Onset of psoriasis reason more complicated, the cause of disease is not yet clear and definite.Most scholars think in recent years, relevant with heredity, infection, dysbolismus, immune dysfunction, endocrine disturbance.Become now more and more general, the city of particularly having developed.Psoriasis is not a kind of infectious disease, but because psoriatic's skin problem often brings great body and mind misery and financial burden to patient.
Western medical treatment psoriasis is mainly to eliminate symptom, avoids further deterioration, cannot effect a radical cure.Side effect is larger.Because psoriatic pathological change is epidermal cell proliferation, so all focused on using the cancer therapy drug that can suppress cell proliferation in the past, reinstate aminopterin the fifties, use after a while methotrexate (METHOTREXOTE), reinstate the seventies such as ethyliminum, bimolane etc., but these drug side effectes are large, and easily recurrence after drug withdrawal, then the state of an illness is often heavier while sending out, treat also more obstinate, as aminopterin easily causes leukopenia, even granulocyte lacks, and also can cause liver cirrhosis and hepatocarcinoma.Methotrexate is larger to the toxicity of liver; Because using ethyliminum and bimolane, in recent years district in all parts of the country oneself have tens of examples to cause leukemic report.And traditional Chinese medical science traditional remedies is treated psoriasis because therapeutic effect can not quantize, neither be very desirable.
In Chinese patent application CN 03128560.0 and CN 01118726.3, recorded a kind of Bulgaria inquinans or its mycelial extract is used for the treatment of psoriasis, this medicine has certain curative effect, does not produce at present and goes on the market, and need to further study.
Scientific and technical literature " Jing Haixia; Sheng Wanxiang; Duan Dejian etc.; at Radix Angelicae Sinensis polysaccharide on the impact of Expression Levels of PCNA in Psoriasis-like Lesions of Guinea Pigs [J]. Chinese skin cypridology magazine; 01 phase in 2008 " in, reported the impact of Radix Angelicae Sinensis polysaccharide on cell proliferative nuclear antigen (PCNA) expression in Cavia porcellus ear Pigs with Psoriasis, research conclusion is that the hard of hearing Psoriasis-like Model of Cavia porcellus that Radix Angelicae Sinensis polysaccharide brings out Propranolol has therapeutical effect, may be relevant with PCNA expression in its reduction skin lesion.
Summary of the invention
For solving above-mentioned problems of the prior art, the invention provides a kind of psoriatic medicine and preparation method thereof for the treatment of.
Particularly, the invention provides:
(1) a psoriatic medicine, wherein, this medicine is made by the crude drug of following weight portion: Bulgaria inquinans 6-10 part, Radix Angelicae Sinensis 6-12 part, Cortex Dictamni 6-15 part, Radix Glycyrrhizae 3-9 part.
(2) according to the medicine (1) described, wherein, the weight portion of described crude drug is respectively: 10 parts of Bulgaria inquinanss, 10 parts of Radix Angelicae Sinensis, 10 parts of Cortex Dictamni, 6 parts, Radix Glycyrrhizae.
(3) a psoriatic medicine, wherein, this medicine is made by the crude drug of following weight portion: Bulgaria inquinans 6-10 part, Radix Angelicae Sinensis 6-12 part, Cortex Dictamni 6-15 part, Radix Glycyrrhizae 3-9 part, Radix Salviae Miltiorrhizae 9-15 part.
(4) according to the medicine (3) described, wherein, the weight portion of described crude drug is respectively: 10 parts of Bulgaria inquinanss, 10 parts of Radix Angelicae Sinensis, 10 parts of Cortex Dictamni, 6 parts, Radix Glycyrrhizae, 10 parts of Radix Salviae Miltiorrhizaes.
(5) extracting method for the medicine in (1)-(4) described in any one, it comprises:
By described crude drug coarse pulverization, with the alcohol reflux of 3-7 times of weight 2-4 time, each extraction time is 1-3 hour successively, filter, and merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, thus obtain extract.
(6) extracting method according to (5), it comprises: by described crude drug coarse pulverization, use successively the alcohol reflux 3 times of 5 times of weight, time is respectively 2 hours, 1.5 hours, 1.5 hours, filters merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, thus obtain described extract.
(7) extract that the described extracting method in a kind of basis (5) or (6) obtains.
(8) extract described in basis (7) is in the purposes for the preparation of in the psoriatic medicament for the treatment of.
(9) preparation method for the capsule of the medicine in (1)-(4) described in any one, it comprises:
A), by described crude drug coarse pulverization, with the alcohol reflux of 3-7 times of weight 3 times, each extraction time is 1-3 hour successively, filter, and merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, thus obtain extract;
B) get the extract that step a) obtains and mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, under 60 ℃ of-70 ℃ of conditions, dry, pulverize is 80 order fine powders, pours into capsule, obtains capsule.
(10) capsule that the described preparation method of a kind of basis (9) obtains.
Medicine of the present invention compared with prior art has the following advantages and good effect:
That medicine of the present invention has is antipruritic, calm, blood circulation promoting and blood stasis dispelling, reduction blood viscosity, improve microcirculation, heat clearing and damp drying, removing toxic substances, antibiotic effect, it has certain photodynamics can increase therapeutic effect, and medicine of the present invention has the psoriatic effect of significant treatment especially.
The specific embodiment
Below the invention will be further described for the description by the specific embodiment, but this is not limitation of the present invention, those skilled in the art are according to basic thought of the present invention, can make various modifications or improvement, but only otherwise depart from basic thought of the present invention, all within the scope of the present invention.
The inventor have been surprisingly found that by a large amount of research, and the combination medicine form of Bulgaria inquinans, Radix Angelicae Sinensis, Cortex Dictamni, Radix Glycyrrhizae can provide the useful especially psoriatic effect for the treatment of, and its effect is better than any one-component.
The drug action mechanism of Combined effects of the present invention is:
Bulgaria inquinans is the dry sporophore of the fungus Bulgaria inquinans Bulgaria inquinans of Bulgaria inquinans section (Pers.) Fr., summer and autumn gather, dry, Forest in Changbai Mountain Forest Region, the place of production, after common local resident's continuous several times or once excessive edible glue gyro, through exposure in sunshine, the body exposure positions such as face occur red and swollen, especially with lip, attach most importance to.Therefore locality claims that again Bulgaria inquinans is " snoot mushroom " or " arch mouth mushroom ".
The main chemical compositions of Bulgaria inquinans is ergosterol, oxalic acid, galactitol and benzofluoranthrene quinones etc.Bulgaria inquinans has the effect of heat-clearing and toxic substances removing, promoting blood circulation to remove obstruction in the collateral, the psoriatic pharmacological action of Bulgaria inquinans extract for treating is very special, be different from traditional Chinese medicine, after taking, patient there is photodynamic effect (photosensitivity reaction), can be rubescent after solar radiation and have a reaction of similar inflammation in affected part, within after drug withdrawal 1-2 days, disappear, this process has benefit very to psoriatic recovery from illness.This photodynamic effect is similar to the photochemotherapy (PUVA) in western medicine, and there is no the common toxic and side effects of photochemotherapy.
Radix Angelicae Sinensis has the effect of enriching blood and invigorating blood circulation, and its chemical composition is mainly volatile oil composition and polysaccharide composition, for example butylidenephthalide (Butylidene phthalide), nopinene (β-Pinene), australene, camphene (Camphene), to P-cymene (p-Cymene), β-phellandrene (β-Phellandrene), myrcene (Myrcene), alloocimene (Allo-ocimene), 6-normal-butyl-cycloheptadiene-Isosorbide-5-Nitrae (6-n-butyl-cycloheptadiene-1,4), 2-methyl-dodecane-5-ketone (2-Methyl-dodecane-5-one), 1-Phenylethanone. (Acetophenone), β-bisabolence (β-Bisabolene), different Rhizoma Acori Graminei alkene (Isoacroraene), acoradiene (Acoradiene), cuparene (Chamigrene), α-himachalene (α-Cedrene), ligustilide (Ligustilide), normal-butyl Si Qingization Fu lactone (n-Butyl-tetrahydrophthalide), Zheng butylphthalide (n-Butyl-phthalide), Zheng Ding Xi Fu lactone (n-Buty-lidene phthalide), n-dodecane alcohol (Dodecanol), bergapton (Bergapten) etc.There is blood vessel dilating, promote humoral immunization, antibiotic effect.
Cortex Dictamni has heat clearing and damp drying, dispelling wind for relieving itching, the effect of removing toxic substances, its chemical composition is mainly dictamine (dictamnine), .beta.-fagarine (skimmianine), .gamma.-fagarine (g-fagarine), front .beta.-fagarine (preskimmianine), the different speckle forest-grass alkali (isomaculosindine) that boils, limonin (limonin, dictamnolactone), obacunone (obakunone), fraxinellon (fraxinellone), and sitosterol, acidic materials and Saponin etc. Herb is still containing 7-geranyloxycoumarin (aurapten), Bergapten (bergapten). aerial parts is also containing psoralen (psoralen), xanthotoxin (xanthotoxin) and volatile oil, root bark is still containing campesterol (campesterol).There is antibiotic, antifungal, analgesic, the effect that increases cardiac muscular tension.
Radix Glycyrrhizae has the effect of heat-clearing and toxic substances removing, its chemical composition is mainly glycyrrhizic acid, liquiritin etc., such as: glycyrrhizin, enoxolone, liquiritin, isoliquiritin, neoliquriitin, neoisoliquiritin, glycyrrhizin, isoliquiritigenin and licoricidin (+)-Licoricidin., glycyrol, isoglycyrol, 7-methylcoumarin essence, umbelliferone etc.There is the effect of antibiotic, antiinflammatory, antiallergic action, removing toxic substances, and have the effect of adrenocortical hormone sample.
Pharmaceutical composition of the present invention has been followed the theory of traditional Chinese medical science monarch, followed the theory of instruction of Chinese Medicine theory Chinese medicine application, Bulgaria inquinans, Radix Angelicae Sinensis, Cortex Dictamni, Radix Glycyrrhizae four Chinese medicine are according to monarch prescription, wherein, Bulgaria inquinans be monarch drug, when being classified as ministerial drug, Cortex Dictamni is that adjuvant drug, Radix Glycyrrhizae are for making medicine.
The angle of modern Chinese medicine chemistry, four Chinese medicine chemical constituent of the present invention is definite, Bulgaria inquinans mainly contains that ergosterol, oxalic acid, galactitol and benzofluoranthrene quinones composition, Radix Angelicae Sinensis mainly contain volatile oil composition and polysaccharide composition, Cortex Dictamni mainly contains alkaloids composition, Radix Glycyrrhizae and mainly contains glycyrrhizic acid constituents, crude drug effective ingredient after extracting is concentrated, and drug effect is obvious.
Bulgaria inquinans, Radix Angelicae Sinensis, Cortex Dictamni, Radix Glycyrrhizae therapeutic alliance psoriasis have shown the effect of significant Synergistic, and curative effect is better than any one-component.Wherein, Bulgaria inquinans can play heat-clearing and toxic substances removing, promoting blood circulation to remove obstruction in the collateral, antipruritic, calm effect as monarch drug, it has certain photodynamics can increase therapeutic effect, Radix Angelicae Sinensis as ministerial drug have enrich blood invigorate blood circulation, blood vessel dilating, antibiotic effect, Cortex Dictamni has the effect of heat clearing and damp drying, dispelling wind for relieving itching, removing toxic substances as adjuvant drug, Radix Glycyrrhizae, as making medicine, has effect antibiotic, removing toxic substances.Four common onsets, the effect of heat-clearing and toxic substances removing, promoting blood circulation to remove obstruction in the collateral, antipruritic, calm, antibiotic, removing toxic substances, have can highly significant alleviate and reverse psoriasis pathology and change, have and treat especially significantly psoriatic effect.
In addition, the present invention, on the basis of above-mentioned four medicines, can increase Radix Salviae Miltiorrhizae again.Radix Salviae Miltiorrhizae has the effect of blood circulation promoting and blood stasis dispelling, its chemical composition is mainly: diterpene Quinone Pigments, TANSHINONES (tanshinone) I, II A, II B, cryptotanshinone (cryptotanshinone), iso tanshinone (isotanshinones) I, II, different cryptotanshinone (1socryptotanshinone), miltirone (miltirone), Methyl tanshinoate (methyl tanshinonate), hydroxytanshinone ⅡA Hydroxytanshinone IIA. (hydroxytanshinone), dihydrotanshinone Ⅰ (dihydrotanshinone I), neotanshinone A, second, third, methylene tanshinquinone (methylenetanshinquinone) and carnosol (salviol).Another report closes ferruginal (ferruginol), Δ l-miltirone (Δ l-dehydromiltirone), Δ l-tanshinone IIA (Δ l-dehydrotanshinone IIA), danshenxinkun fourth (danshenxinkun D) and 1,2-dihydro Radix Salviae Miltiorrhizae quinone etc.There is the effect that improves microcirculation, the reparation that promotes tissue and regeneration, suppresses the fibroblast of hyperplasia.In the present invention, further, Radix Salviae Miltiorrhizae can be ministerial drug with Radix Angelicae Sinensis altogether, plays further reduction psoriatic blood viscosity, improves microcirculatory effect.
Particularly, the invention provides a kind of psoriatic medicine for the treatment of, this medicine is made by the crude drug that comprises Bulgaria inquinans, Radix Angelicae Sinensis, Cortex Dictamni, Radix Glycyrrhizae, also can comprise pharmaceutically acceptable pharmaceutic adjuvant.
Prepare the crude drug that medicine of the present invention adopts, according to the ratio of the weight of crude drug, comprise Bulgaria inquinans 6-10 part, Radix Angelicae Sinensis 6-12 part, Cortex Dictamni 6-15 part, Radix Glycyrrhizae 3-9 part.
Prepare the crude drug that medicine of the present invention adopts, according to the ratio of the weight of crude drug, further preferably include 10 parts of Bulgaria inquinanss, 10 parts of Radix Angelicae Sinensis, 10 parts of Cortex Dictamni, 6 parts, Radix Glycyrrhizae.
Further preferably, prepare the crude drug that medicine of the present invention adopts, according to the ratio of the weight of crude drug, contain Bulgaria inquinans 6-10 part, Radix Salviae Miltiorrhizae 9-15 part, Radix Angelicae Sinensis 6-12 part, Cortex Dictamni 6-15 part, Radix Glycyrrhizae 3-9 part.More preferably contain 10 parts of Bulgaria inquinanss, 10 parts of Radix Salviae Miltiorrhizaes, 10 parts of Radix Angelicae Sinensis, 10 parts of Cortex Dictamni, 6 parts, Radix Glycyrrhizae.
In order to reach more concentrated pharmacological action and better drug effect, preferably crude drug Bulgaria inquinans, Radix Angelicae Sinensis, Cortex Dictamni, Radix Glycyrrhizae are made to medicine of the present invention through extraction process.
Can be obtained by methods such as conventional water extraction, ethanol extraction, water extract-alcohol precipitations, preferably by following method, extract and obtain:
Crude drug coarse pulverization, with the alcohol reflux of 3-7 times of weight 2-4 time, each extraction time is 1-3 hour successively, filter, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains getting thing.
Further preferred extracting method is: crude drug coarse pulverization, use successively the alcohol reflux 3 times of 5 times of weight, and the time is 2 hours, 1.5 hours, 1.5 hours, filters, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract.
Medicine preferred oral of the present invention administration, is also applicable to other administering mode, as parenteral, sublingual administration or oral transmucosal administration etc.
The oral administration form of medicine of the present invention can be any conventional formulation forms such as tablet, capsule, granule, oral liquid, mixture, effervescent tablet, oral cavity disintegration tablet.Capsule preferably.
The preparation method of the capsule of medicine of the present invention is preferably:
A) crude drug coarse pulverization, the alcohol reflux of doubly measuring with 3-7 successively 3 times, each extraction time is 1-3 hour, filters, merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing and mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, under 60 ℃ of-70 ℃ of conditions, dry, pulverize is 80 order fine powders, pours into capsule, obtains capsule.
Mode by the following examples further explains and describes content of the present invention, but these embodiment are not to be construed as limiting the scope of the invention.
Embodiment 1
A) above-mentioned raw materials medicine coarse pulverization, uses the alcohol reflux 3 times of 5 times of weight successively, and the time is 2 hours, 1.5 hours, 1.5 hours, filter, and merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing and mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, under 60 ℃ of-70 ℃ of conditions, dry, pulverize is 80 order fine powders, fill capsule.
Embodiment 2
A) above-mentioned raw materials medicine coarse pulverization, uses the alcohol reflux 3 times of 5 times of weight successively, and the time is 2 hours, 1.5 hours, 1.5 hours, filter, and merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing and mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, under 60 ℃ of-70 ℃ of conditions, dry, pulverize is 80 order fine powders, fill capsule.
Embodiment 3
A) above-mentioned raw materials medicine coarse pulverization, uses the alcohol reflux 3 times of 5 times of weight successively, and the time is 2 hours, 1.5 hours, 1.5 hours, filter, and merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing and mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, under 60 ℃ of-70 ℃ of conditions, dry, pulverize is 80 order fine powders, fill capsule.
Embodiment 4
A) above-mentioned raw materials medicine coarse pulverization, uses the alcohol reflux 3 times of 5 times of weight successively, and the time is 2 hours, 1.5 hours, 1.5 hours, filter, and merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing and mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, under 60 ℃ of-70 ℃ of conditions, dry, pulverize is 80 order fine powders, fill capsule.
Embodiment 5
A) above-mentioned raw materials medicine coarse pulverization, uses the alcohol reflux 3 times of 5 times of weight successively, and the time is 2 hours, 1.5 hours, 1.5 hours, filter, and merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing and mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, under 60 ℃ of-70 ℃ of conditions, dry, pulverize is 80 order fine powders, fill capsule.
Embodiment 6
A) above-mentioned raw materials medicine coarse pulverization, uses the alcohol reflux 3 times of 5 times of weight successively, and the time is 2 hours, 1.5 hours, 1.5 hours, filter, and merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, obtains extract;
B) get said extracted thing and mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, under 60 ℃ of-70 ℃ of conditions, dry, pulverize is 80 order fine powders, fill capsule.
Below by test example, further verify the beneficial effect of medicine of the present invention:
Test example 1: the impact of medicine of the present invention on Animal Models of Psoriasis---medicine of the present invention is on the mitotic impact of mice estrogen phase vaginal epithelial cell
Experiment purpose: psoriatic pathological characters is skin lesion position epidermis cell hyper-proliferative and parakeratosis.Mouse vagina epithelial cell proliferation in the estrogen phase is active, is the common model of evaluating curing psoriasis medicine.
Experimental agents: medicine group of the present invention is drug extract extract powder of the present invention, is mixed with debita spissitudo before use with distilled water; Blank group is distilled water; Positive control drug group is Etretinate granule (Radix Sophorae Flavescentis, Radix Glycyrrhizae, Cortex Dictamni, Radix Saposhnikoviae, Rhizoma Smilacis Glabrae, Periostracum Cicadae, Cortex Phellodendri, Radix Rehmanniae, Flos Lonicerae, Radix Paeoniae Rubra, Fructus Forsythiae, Radix Angelicae Sinensis); Bulgaria inquinans extract group, Radix Angelicae Sinensis extract group, Radix Salviae Miltiorrhizae extract group, Cortex Dictamni extract group, Radix Glycyrrhizae extract group, for extract the extract obtaining with reference to the method described in embodiment 1, are mixed with debita spissitudo with distilled water before use.
Experimental technique: 130 of Kunming kind female mices, 20-30g/, lumbar injection diethylstilbestrol 0.2mg/, every day 1 time, continuous 3 days, make it in the estrogen phase, within 4th, be divided at random 13 groups, 10 every group.Press table 3 grouping, every day, gastric infusion was 1 time, continuous 3 days, after last administration, 2 hours lumbar injection colchicine 2mg/kg, put to death mice after 4 hours and get vagina, and 10% formalin is fixed, the conventional film-making of paraffin embedding, HE dyes, and counts the mitosis number of 300 vagina epithelium basal cells under light microscopic, and its percentage rate is mitotic index.
Experimental result is in Table 1.
Table 1: medicine of the present invention is on the mitotic impact of mice estrogen phase vaginal epithelial cell (n=10)
Experiment conclusion: medicine of the present invention has obvious inhibitory action (P < 0.05, P < 0.01) to mice estrogen phase vaginal epithelial cell mitosis.Wherein, the pharmacological action of the middle and high dosage group of medicine of the present invention is obviously better than positive control drug Etretinate granule.And the pharmacological action of medicine group of the present invention is obviously better than single Radix Salviae Miltiorrhizae extract group, Bulgaria inquinans extract group, Radix Angelicae Sinensis extract group, Cortex Dictamni extract group and Radix Glycyrrhizae extract group, thereby medicine of the present invention has synergy.
Test example 2: the impact that medicine of the present invention generates mouse tail epidermal granular cell the impact of Animal Models of Psoriasis-medicine of the present invention
Experiment purpose: psoriatic pathological characters is skin lesion position epidermis cell hyper-proliferative and parakeratosis.The keratinization of mouse tail epidermis forms similar to mankind psoriatic, lacks granular cell, is the common model of evaluating curing psoriasis medicine.
Experimental agents: medicine group of the present invention is drug extract extract powder of the present invention, is mixed with debita spissitudo before use with distilled water; Blank group is distilled water; Positive control drug group is Etretinate granule (Radix Sophorae Flavescentis, Radix Glycyrrhizae, Cortex Dictamni, Radix Saposhnikoviae, Rhizoma Smilacis Glabrae, Periostracum Cicadae, Cortex Phellodendri, Radix Rehmanniae, Flos Lonicerae, Radix Paeoniae Rubra, Fructus Forsythiae, Radix Angelicae Sinensis); Bulgaria inquinans extract group, Radix Angelicae Sinensis extract group, Radix Salviae Miltiorrhizae extract group, Cortex Dictamni extract group, Radix Glycyrrhizae extract group, for extract the extract obtaining with reference to the method described in embodiment 1, are mixed with debita spissitudo with distilled water before use.
Experimental technique: 130 of Kunming mouses, 20-30g/ only, is divided into 13 groups at random by table 4, and 10 every group, male and female half and half, every day, gastric infusion was 1 time, successive administration 20 days.Within after last administration 2 hours, put to death whole mices, get apart from the Mus root of the tail 1.8cm of portion place dorsal skin one rectangularly, 10% formalin is fixed, the conventional film-making of paraffin embedding, and HE dyeing, counts 10 middle eyepiece micrometer scope 132 μ m endoparticle cell number of scale under light microscopic.
Experimental result is in Table 2.
Table 2: the impact that medicine of the present invention generates mouse tail epidermal granular cell
Experiment conclusion: medicine of the present invention has obvious facilitation (P < 0.05, P < 0.01) to the generation of mouse tail granular cell, granular cell showed increased, Keratoderma layer obviously thickens.Wherein, the pharmacological action of the middle and high dosage group of medicine of the present invention is obviously better than positive control drug Etretinate granule.And the pharmacological action of medicine group of the present invention is obviously better than single Radix Salviae Miltiorrhizae extract group, Bulgaria inquinans extract group, Radix Angelicae Sinensis extract group, Cortex Dictamni extract group and Radix Glycyrrhizae extract group, thereby medicine of the present invention has synergy.
Claims (10)
1. be used for the treatment of a psoriatic medicine, wherein, this medicine is made by the crude drug of following weight portion: Bulgaria inquinans 6-10 part, Radix Angelicae Sinensis 6-12 part, Cortex Dictamni 6-15 part, Radix Glycyrrhizae 3-9 part.
2. medicine according to claim 1, wherein, the weight portion of described crude drug is respectively: 10 parts of Bulgaria inquinanss, 10 parts of Radix Angelicae Sinensis, 10 parts of Cortex Dictamni, 6 parts, Radix Glycyrrhizae.
3. be used for the treatment of a psoriatic medicine, wherein, this medicine is made by the crude drug of following weight portion: Bulgaria inquinans 6-10 part, Radix Angelicae Sinensis 6-12 part, Cortex Dictamni 6-15 part, Radix Glycyrrhizae 3-9 part, Radix Salviae Miltiorrhizae 9-15 part.
4. medicine according to claim 3, wherein, the weight portion of described crude drug is respectively: 10 parts of Bulgaria inquinanss, 10 parts of Radix Angelicae Sinensis, 10 parts of Cortex Dictamni, 6 parts, Radix Glycyrrhizae, 10 parts of Radix Salviae Miltiorrhizaes.
5. according to an extracting method for the medicine described in any one in claim 1-4, it comprises:
By described crude drug coarse pulverization, with the alcohol reflux of 3-7 times of weight 2-4 time, each extraction time is 1-3 hour successively, filter, and merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, thus obtain extract.
6. extracting method according to claim 5, it comprises: by described crude drug coarse pulverization, use successively the alcohol reflux 3 times of 5 times of weight, time is respectively 2 hours, 1.5 hours, 1.5 hours, filter merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, thus described extract obtained.
7. the extract obtaining according to the extracting method described in claim 5 or 6.
8. extract according to claim 7 is in the purposes for the preparation of in the psoriatic medicament for the treatment of.
9. according to a preparation method for the capsule of the medicine described in any one in claim 1-4, it comprises:
A), by described crude drug coarse pulverization, with the alcohol reflux of 3-7 times of weight 3 times, each extraction time is 1-3 hour successively, filter, and merging filtrate, decompression recycling ethanol, concentrating under reduced pressure, thus obtain extract;
B) get the extract that step a) obtains and mix homogeneously by the weight ratio of 1:1:0.5 with starch, microcrystalline Cellulose, under 60 ℃ of-70 ℃ of conditions, dry, pulverize is 80 order fine powders, pours into capsule, obtains capsule.
10. the capsule that preparation method according to claim 9 obtains.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210225558.0A CN103505535B (en) | 2012-06-29 | 2012-06-29 | Medicine used for treating psoriasis as well as extraction method, extract and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201210225558.0A CN103505535B (en) | 2012-06-29 | 2012-06-29 | Medicine used for treating psoriasis as well as extraction method, extract and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN103505535A true CN103505535A (en) | 2014-01-15 |
| CN103505535B CN103505535B (en) | 2015-05-06 |
Family
ID=49889308
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201210225558.0A Expired - Fee Related CN103505535B (en) | 2012-06-29 | 2012-06-29 | Medicine used for treating psoriasis as well as extraction method, extract and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103505535B (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578461A (en) * | 2018-01-22 | 2018-09-28 | 河南大学 | Cercis extract and its extracting method and the application in terms of preparing antithrombotic reagent |
| CN115531407A (en) * | 2022-10-27 | 2022-12-30 | 黑龙江中医药大学 | Pharmaceutical composition for treating psoriasis, preparation and application thereof |
Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1390602A (en) * | 2001-06-08 | 2003-01-15 | 中国高科集团股份有限公司北京分公司 | Extract of Jiaotuo conch or its mycelium and preparing process and applicatino of its medicine |
| CN1506110A (en) * | 2000-08-04 | 2004-06-23 | 中国高科集团股份有限公司 | Application of Bulgaria inquinans or its mycelium in preparing medicine |
| CN1714840A (en) * | 2004-06-28 | 2006-01-04 | 广西玉林制药有限责任公司 | Chinese medicine composition for stopping itching and its preparing method |
| CN101757104A (en) * | 2009-12-22 | 2010-06-30 | 北大方正集团有限公司 | Medicament for treating psoriasis |
-
2012
- 2012-06-29 CN CN201210225558.0A patent/CN103505535B/en not_active Expired - Fee Related
Patent Citations (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1506110A (en) * | 2000-08-04 | 2004-06-23 | 中国高科集团股份有限公司 | Application of Bulgaria inquinans or its mycelium in preparing medicine |
| CN1390602A (en) * | 2001-06-08 | 2003-01-15 | 中国高科集团股份有限公司北京分公司 | Extract of Jiaotuo conch or its mycelium and preparing process and applicatino of its medicine |
| CN1714840A (en) * | 2004-06-28 | 2006-01-04 | 广西玉林制药有限责任公司 | Chinese medicine composition for stopping itching and its preparing method |
| CN101757104A (en) * | 2009-12-22 | 2010-06-30 | 北大方正集团有限公司 | Medicament for treating psoriasis |
Non-Patent Citations (1)
| Title |
|---|
| 黄锦兆: "中医药治疗银屑病20例体会", <<实用中西医结合临床>>, vol. 9, no. 4, 31 July 2009 (2009-07-31), pages 74 - 75 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108578461A (en) * | 2018-01-22 | 2018-09-28 | 河南大学 | Cercis extract and its extracting method and the application in terms of preparing antithrombotic reagent |
| CN115531407A (en) * | 2022-10-27 | 2022-12-30 | 黑龙江中医药大学 | Pharmaceutical composition for treating psoriasis, preparation and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN103505535B (en) | 2015-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG188283A1 (en) | Pharmaceutical composition for treating insomnia and preparation method thereof | |
| CN104138550A (en) | Preparation method of medicine for treating peptic ulcers | |
| CN103386022B (en) | Chinese medicine composition for treating tuberculous pleurisy | |
| CN103006822B (en) | Application of American ginseng in preparing medicament for preventing and treating alcoholic liver injury | |
| CN101933973B (en) | Medicament composition for preventing and treating liver damage | |
| CN103505535B (en) | Medicine used for treating psoriasis as well as extraction method, extract and application thereof | |
| CN102228544B (en) | Traditional Chinese medicine composition for treating leucoderma and preparation method thereof | |
| CN111375038B (en) | Traditional Chinese medicine bath composition for treating psoriasis as well as preparation method and application thereof | |
| CN107569528A (en) | A kind of pharmaceutical composition for treating hepatitis, pharmaceutical preparation and application and preparation method | |
| CN101757104B (en) | Medicament for treating psoriasis | |
| CN114344423A (en) | Traditional Chinese medicine composition for treating atopic dermatitis and application thereof | |
| CN102698214A (en) | Traditional Chinese medicine for treating migraine and preparation method thereof | |
| CN102228591A (en) | Preparation method of oral medicinal preparation for regulating menstruation and stopping pains | |
| KR100821631B1 (en) | A beauty food composition containing oriental medicine extract for improvement of skin condition | |
| CN102526385B (en) | Medicament for treating climacteric syndrome | |
| CN105435196A (en) | Externally-applied traditional Chinese medicine ointment for treating qi stagnation and blood stasis coronary angina pectoris with chronic gastritis and preparation method thereof | |
| CN103520475B (en) | A kind of pharmaceutical composition being used for the treatment of skin pruritus | |
| CN104547309A (en) | Traditional Chinese medicine composition for removing chloasma, and preparation method and application thereof | |
| CN104274555B (en) | Traditional Chinese medicine composition for treating rheumatism, ointment and preparation method of traditional Chinese medicine composition | |
| CN110841007B (en) | Traditional Chinese medicine composition for treating cerebral apoplexy sequela and application thereof | |
| CN102357175B (en) | Traditional Chinese medicine composite for regulating nervous system dysfunction and application thereof | |
| CN115068561A (en) | Traditional Chinese medicine composition for treating atopic dermatitis and application thereof | |
| CN1123138A (en) | "Jiangyaning"-natural health-care bath lotion capable of permeating skin for step-down of hypertension and preparation thereof | |
| CN105311335A (en) | Traditional Chinese medicine composition for assisting tumor chemoradiotherapy | |
| CN105106555A (en) | Traditional chinese medicine for treating gastric cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP01 | Change in the name or title of a patent holder |
Address after: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee after: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: PKU HEALTHCARE INDUSTRY Group Address before: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: Pku Healthcare Industry Group Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20221020 Address after: 3007, Hengqin international financial center building, No. 58, Huajin street, Hengqin new area, Zhuhai, Guangdong 519031 Patentee after: New founder holdings development Co.,Ltd. Patentee after: PKUCARE PHARMACEUTICAL R&D CENTER Patentee after: Peking University Medical Management Co.,Ltd. Address before: 100871, Beijing, Haidian District, Cheng Fu Road, No. 298, Zhongguancun Fangzheng building, 5 floor Patentee before: PEKING UNIVERSITY FOUNDER GROUP Co.,Ltd. Patentee before: PKUCARE PHARMACEUTICAL R&D CENTER Patentee before: PKU HEALTHCARE INDUSTRY Group |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20150506 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |